Isoprotrace (Gozetotide)

Gozetotide is a monoclonal antibody that binds to a specific cell‑surface receptor involved in disease signaling. By blocking this receptor, it prevents downstream activation of pathways that drive abnormal cell growth and immune responses, aiming to modify disease progression.

The dosing regimen for Isoprotrace is determined by the prescribing physician based on the specific clinical trial protocol, patient characteristics, and therapeutic goals. No standard dose can be provided without a qualified medical assessment.

Safety data for Gozetotide in pregnancy or lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Isoprotrace (Gozetotide) is a biologic monoclonal antibody, differing from small‑molecule drugs or conventional chemotherapy. Its targeted mechanism may offer advantages in specificity and reduced off‑target effects, but comparative efficacy and safety depend on the disease context and are still being defined in clinical studies.

Isoprotrace should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability until it is prepared for intravenous administration.

Isoprotrace is administered by intravenous infusion under the supervision of qualified healthcare personnel. The infusion rate and duration are determined by the treating physician and the specific clinical protocol being followed.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, cytokine release syndrome, significant infections due to immunosuppression, liver toxicity, and rare thromboembolic or bleeding events. Patients should be closely monitored during and after infusion.

Isoprotrace should not be used in individuals with a known hypersensitivity to Gozetotide or any of its excipients, in patients receiving live vaccines, or in those for whom the risk of severe immunosuppression outweighs potential benefits, as determined by a qualified clinician.